Compare MDXH & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDXH | QSI |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | Belgium | United States |
| Employees | N/A | 145 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.0M | 161.8M |
| IPO Year | 2021 | N/A |
| Metric | MDXH | QSI |
|---|---|---|
| Price | $2.29 | $1.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $7.67 | $1.00 |
| AVG Volume (30 Days) | 210.3K | ★ 4.4M |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.78 | N/A |
| Revenue Next Year | $18.31 | $618.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $0.69 |
| 52 Week High | $5.33 | $3.10 |
| Indicator | MDXH | QSI |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 63.68 |
| Support Level | $1.93 | $0.90 |
| Resistance Level | $2.75 | $1.08 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 80.54 | 82.17 |
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Quantum-Si Inc is a life sciences company focused on proteomics research and analytical technologies. It develops single-molecule detection platforms designed to enable next-generation protein sequencing (NGPS) and large-scale protein analysis. Its technology supports massively parallel sequencing of proteins and can also be applied to the study of nucleic acids, providing tools for researchers and clinical applications in molecular analysis. The company's revenue is derived from sales of products and services.